Skip to main content

Table 1 Summary of study design

From: Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer

Investigator Year Location Pop. Characteristics Publication type Study Design N Median Age Treatment technique QOL tool Assessment Timeline
Thibault [21] 2014 Canada Mets (30) Conference Abstract Prospective Longitudinal Cohort 30 65 (40–88) SBRT
30-60Gy, 3-6#
QLQ-C15PAL QLQ-LM21 Baseline, 1, 6, 12 weeks post treatment
Shun [22] 2008 Taiwan HCC (99) Journal article Prospective Longitudinal Cohort 99 62.42 (12.6) SRT - Mean dose 42.6Gy FLIC-QOL 1 week pre treatment, weekly x6 weeks during
Mendez Romero [20] 2008 Netherlands Mets (19)
HCC (9)
Journal article Prospective Longitudinal Cohort 25 68 (37–81) SBRT
3x12.5Gy
5x5Gy
3x10Gy
EQ-5D
EQ-5D VAS
QLQ C-30
1 month pre + 1, 3, 6 months post treatment
Klein [18] 2015 Canada Mets (86)
HCC (98)
IHC (21)
Journal article Prospective Longitudinal Cohort 205 67 (30–90) Image guided SBRT
24–60 GY/6#
QLQ-C30
FACT-Hep
Baseline and 1,3,6,12 months post treatment
Law [19] 2012 Hong Kong HCC (33) Journal article Prospective Longitudinal Cohort 33 69 (47–89) Highly-conformal RT
55GY/10#
FACT-Hep Baseline, 3, 6 months